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thetical cohort of 1,000 PCI patients/year (STEMI= 6.4%, NSTEMI/UA= 16.7%, stable 
angina= 76.9%) treated with heparin+/-GPI (weighted average of 30.0% GPI use across 
diagnoses), use of bivalirudin+cangrelor+2.8% GPI provided a hospital $0.95MM in 
clinical value. Cost-offsets were derived from a reduction in GPI use, lower ischemic 
and bleeding events. Sensitivity was assessed in using heparin+/-GPI; GPI%= 70.6% 
(extreme from APEX-AMI trial) vs. bivalirudin+cangrelor+9.7% GPI where the clini-
cal value was estimated at $1.59MM. ConClusions: Use of bivalidudin+cangrelor 
during PCI delivers an estimated clinical value of at least $950 per PCI-patient, $1,590 
in STEMI patients with improved clinical outcomes.
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An EConomiC EVAluAtion of HosPitAl REsouRCE usE And Costs 
AssoCiAtEd WitH A nEW And innoVAtiVE suRgERy systEm in PACEmAkER 
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objeCtives: Complications like mechanical lead damage, major infections and 
hematomas during surgical replacement of pacemaker and implantable cardioverter 
defibrillator contribute to considerable additional costs for hospitals. This study 
aimed to evaluate the economic impact if the currently applied traditional surgical 
intervention (TSI) by using scissors, scalpels and electrocautery is replaced by a 
new and innovative surgical system, called PEAK PlasmaBladeTM (PPB). Methods: 
A retrospective analysis examined 508 patients with TSI and 84 patients with PPB, 
who underwent generator replacement at the general hospital in Linz, Austria. 
Intraoperative complications (lead damages, infections, hematomas) and duration 
of operating time for TSI and PPB were analyzed. Economic analysis included the 
costs for personnel, facility and consumables as well as the estimates for the budget 
impact. Results: Proportion of males (TSI = 59.4%; PPB = 63.1%) and mean age (TSI 
= 74.3±12.4, PPB = 74.2±12.9 years) were not significantly different between the two 
groups. The lead damage was significantly higher with TSI than with PPB (5.7% and 
0.0%; p= 0.024) and the operation time with TSI was significantly longer than with 
PPB (47.5±24.0 and 27.8±6.4 minutes; p< 0.0001). Other complications, like revisions 
of hematomas and infections (TSI = 1.6%; PPB = 2.4%), did not significantly differ 
between TSI and PPB. Reduced costs associated with operation room use, hospital 
staff and replacement of damaged leads resulted in a cost saving of € 124 per patient 
when using PPB instead of TSI. Based on estimated 2,600 patients annually under-
going generator replacement in Austria, the use of PPB may result in cost savings 
of € 321,000. ConClusions: PEAK PlasmaBladeTM has the potential to minimize 
the risk of lead damage while decreasing surgery time, resulting in a more efficient 
utilization of the operation room. Along with cost savings and improved quality of 
care hospitals may increase the number of daily surgeries.
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objeCtives: The objective of this analysis is to examine the impact of the new ACC/
AHA clinical practice guideline on pharmacy utilization of cholesterol drugs in a 
managed care setting. Methods: Pharmacy claims from a national PBM over a one 
year period were used to project the number of potential members who will be start-
ing or switching statin therapies. Potential members include members with diabetes 
or hypertension between 40-75 years of age and not on any cholesterol medications 
as well as members receiving lower-intensity statins or other non-statin cholesterol 
therapies. The current cholesterol market share was used to project pharmacy uti-
lization for potential members that will be starting or switching therapies. Expert 
opinion was used in areas where information was not available in the medical 
literature. Results: An estimated 11-19% of commercial and 38-45% of Medicare 
members not receiving any cholesterol agents may be potentially started on statin 
therapies. These new starts, along with the other members who may be switching 
from non-statin cholesterol agents or increasing their statin dosages, will be pro-
jected to increase the number of statin prescriptions approximately 75-80% in the 
commercial and 32-34% in the Medicare population. On the other hand, the number 
of non-statin cholesterol prescriptions is anticipated to decrease 47-67% and 70% 
in the commercial and Medicare population, respectively. ConClusions: The new 
cholesterol guideline is projected to have a huge impact on cholesterol drug utili-
zation.  Estimates are highly dependent on expert opinions and further statistical 
inference models will be applied in future studies to examine these uncertainties.
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ComoRbidity Cost sAVings oVER 2 yEARs of tREAtmEnt WitH 
PHEntERminE And toPiRAmAtE ExtEndEd-RElEAsE (PHEn/tPm ER) in An 
oVERWEigHt And obEsE PoPulAtion
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objeCtives: This post-hoc analysis estimated comorbidity costs over 2 years with 
PHEN/TPM ER 7.5/46 mg compared with lifestyle modification (LM) alone for weight 
management in an overweight/obese population. Methods: A 2-year model was 
developed from a health plan perspective estimating comorbidity cost offsets for 
a reduction in body mass index (BMI) and comorbidity costs for incident cases 
of hypertension, type 2 diabetes mellitus (T2DM), and dyslipidemia. BMI changes 
over 2 years were from SEQUEL, a 52-week extension study of CONQUER, a phase 
3, 56-week trial that randomized patients to PHEN/TPM ER or placebo (all patients 
received LM). Cost offsets for BMI reduction were calculated by multiplying changes 
in BMI by the medical ($164) and pharmacy ($113) cost change per unit of BMI 
(Wang 2006). Incident comorbidity costs were based on patients who progressed 
from no medication use at baseline to use of ≥ 1 medication at endpoint of SEQUEL 
(Garvey 2012). Literature-based cost estimates of the annual cost of treating each 
comorbidity were applied to the rates of disease progression to calculate costs. The 
cost of PHEN/TPM ER was not included in the analysis. Results: BMI reductions 
over 2 years were 3.64kg/m2 for PHEN/TPM ER 7.5/46 and 0.24kg/m2 for LM, trans-
lating to cost offsets of $1008 and $67, respectively. Rates of progression to hyper-
tension (15.8% vs 18.7%), T2DM (2.3% vs 5.6%), and dyslipidemia (12.8% vs 24.0%) 
were lower for PHEN/TPM ER 7.5/46 compared with LM, respectively. Assuming 1% 
market uptake of PHEN/TPM ER 7.5/46 over 2 years, the savings due to BMI-related 
comorbidity cost offsets is $2,769,763 or $0.12 per member per month (PMPM) and 
reduced progression to comorbidities is $1,794,703 or $0.07 PMPM. ConClusions: 
Treatment with PHEN/TPM ER 7.5/46 may be associated with comorbidity cost sav-
ings due to cost offsets for BMI reduction and reduced progression to comorbidities.
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objeCtives: Incremental improvements are inherent in medical devices; many of 
these can offer significant financial benefits which, ultimately, improve the cost-
effectiveness of already established technologies. Biventricular pacing, commonly 
combined with a defibrillator (“Cardiac Resynchronization Therapy – Defibrillator” 
or CRT-D), has been widely used in patients with Heart Failure (HF) to increase 
survival, improve QoL, and reduce HF hospitalizations. Nevertheless, traditional 
CRT-D devices require periodic manual reprogramming (a.k.a. “optimization”) 
guided by echocardiography. Newer devices equipped with innovative algorithms 
(AdaptivCRT™, Medtronic, MN, USA) monitor heart electrical activity and auto-
matically reprogram the device once-per-minute. In addition to eliminating the 
manual process, AdaptivCRT™ appeared to positively impact patient allocation to 
functional classes (as defined by the New York Heart Association – NYHA) against 
traditional echo-based device optimization. We investigated the financial impli-
cations of AdaptivCRT™ in Japan. Methods: We conducted a Cost-Minimization 
Analysis (CMA), comparing AdaptivCRT™ with traditional optimization, using 
Markov processes. Patients progress from early-stage NYHA classes to more 
advanced disease, or death. The initial allocation of patients to the classes and the 
transition probabilities were based on the aCRT RCT. Each NYHA class is associated 
with higher levels of costs. We used the Japanese fee schedule, local HF treatment 
guidelines and prescription drug labelling to assess resource utilization within each 
class. Results: Assuming 3,200 patients (the approximate number of Japanese 
CRT-D patients per annum), our model predicts overall cohort costs (excluding 
initial implant costs) of ¥16,545M (USD$165M) with AdaptivCRT™ and ¥17,809M 
(USD$178M) without. This equates to savings of approximately USD$13M overall, 
or USD$4,000 per patient. ConClusions: AdaptivCRT™ use appears associated 
with significant cost-offsets driven by superior outcomes. This demonstrates that 
incremental device therapy improvements can provide clinical and economic value. 
Further research should examine AdaptivCRT™ impact on health care utility and 
improvement in the overall cost-effectiveness of CRT-Ds.
PCV39
intERACtiVE PRobAbilistiC Cost modEl foR ComPARison REmotE VERsus 
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objeCtives: Develop a probabilistic and comparative cost analysis, from patient 
and hospital perspective of Remote vs. In-Office monitoring in patients with car-
diac rhythm devices. Methods: An economic interactive probabilistic cost model 
was built in excel. The cost variables were identified with patient and hospital 
KOL surveys regarding timing and cost related issues. Secondary data from a 2012 
Heart Rhythm Society study was used. Medical outpatient direct costs were taken 
from the Clinic. Uncertainty adjustment was made to probabilistic variables. Beta, 
normal and Gamma distributions were used for probabilistic, time and cost vari-
ables. Min and max ranges were used when standard deviations were no available. 
After deterministic results, Monte Carlo simulation with 1000 iterations was done. 
The main statistic results obtained were deterministic and probabilistic average 
with their corresponding confident intervals, probabilistic density function and 
cumulative density function. Results: Probabilistic patient total average costs for 
Remote monitoring was US$18.5 (95% CI US$2.0 – US$152.6) in contrast to In-office 
monitoring with US$ 51.41 (95% CI US$ 5.0 – 386.7 US$), which represents a 64% 
cost reduction and a narrow confident interval. Probabilistic outpatient hospital 
total average cost for Remote monitoring was US$33.1 (95% CI US$31 – US$35.2) in 
contrast to In-Office monitoring with US$ 63.9 (95% CI US$ 59.3 –US$68.8), which 
represents a 48% cost reduction and a narrow confident interval. In the cumulative 
distribution function for total patient cost and for total outpatient hospital cost, 
the probability for Remote monitoring to have a lower cost than each considered 
threshold was higher than In-Office interrogation for all values. ConClusions: 
This cost model allows comparing the probabilistic cost distribution of the Remote 
vs. In-Office Interrogation cardiac rhythm devices. The Remote monitoring costs 
are lower for the patient and for the ambulatory hospital services and are more 
predictable than In-Office interrogation costs.
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Costs of isCHEmiC stRokE WitH And WitHout AtRiAl fibRillAtion in 
ColombiA
Castañeda-Cardona C., Rueda J.D., Díaz C.E., Coral Casas J., Rueda M.C., Rosselli D.
Pontificia Universidad Javeriana, Bogotá, Colombia
objeCtives: To estimate total costs and resource use of acute hospital care in 
a sample of patients with large vessel ischemic stroke treated at our University 
Hospital, comparing those with and without non-valvular atrial fibrillation 
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(AF). Methods: We collected a sequential, prospective, convenience sample of 
patients 50 years of age or older, admitted between December 2010 and March 
2013 diagnosed with ischemic stroke, excluding lacunar infarct, transitory cerebral 
ischemia, recurrent stroke or modified Rankin index greater than 2 prior to this 
episode. The presence of AF was sought with electrocardiogram and in some cases 
was studied with Holter. For a separate analysis, we matched for age and admission 
NIHSS score, in a 1:1 ratio, patients with and without AF. Variables measured in all 
cases were: age, gender, admission and discharge NIHSS, modified Rankin index, and 
CHA2DS2VASC score. Prospectively, we collected in-hospital resource use and costs 
incurred during the acute event. Exchange rate 1805 Colombian pesos = 1 American 
dollar (USD). Results: 166 patients were analyzed, 125 without and 41 with non-
valvular AF. For the paired analysis, we considered 37 patients with and 37 without 
AF. The average total cost of acute care for all stroke patients was USD$4,163 (SD 
$7,163) This value was USD$5,729 (SD $8,383) for patients with AF and for patients 
without AF USD$4,464 (SD $6,712). 15 patients (9%) died during the hospitalization, 9 
with AF (22%) and 6 without AF (5%). Of the matched group, 9 of the 37 patients with 
(24%) and 4 of those without (10%) required intensive care. ConClusions: 25% of 
large vessel ischemic stroke patients had AF. Treatment costs are higher in patients 
with AF, since they are older and with more severe strokes. Cost difference is reduced 
and shows no statistical significance when adjusted for age and stroke severity.
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objeCtives: Atrial fibrillation (AF) increases risk of thrombosis (e.g., ischemic stroke 
(IS), myocardial infarction (MI), systemic embolism (SE)). Conversely, thrombosis 
prevention increases bleed risk (e.g., gastrointestinal (GI) bleed, intracranial hemor-
rhage (ICH)). Assessment of the cost-effectiveness of novel anticoagulants (NOACs) 
relies on comparison of costs and outcomes before and after NOAC availability. 
However, published AF-specific costs have limited usefulness because they are out-
dated, limited to Medicare patients, and/or have not captured SE and MI. The objec-
tive of this study is to estimate the incremental costs of ‘events’ (IS, MI, SE, ICH, or GI 
bleed) in patients with AF. Methods: We conducted a matched (1:4), retrospective 
cohort study of patients ≥ 18 years old with incident, AF (ICD-9 427.31) between 2008 
and 2010, identified in the Truvan Health MarketScan® Commercial Claims and 
Medicare Supplemental and Coordination of Benefits Databases. Demographics, 
baseline health care costs, and comorbidities were assessed in the 12 months pre-
ceding AF diagnosis. Cases were defined as having one inpatient admission for an 
event after AF diagnosis followed by 12 months of continuous enrollment. Controls 
were AF patients without an event and 12 months of continuous enrollment after 
a ‘dummy’ event. Multivariate analyses were conducted to assess the incremental 
cost of each event at 30, 90, and 365 days. Results: We identified 1,788 cases and 
7,152 controls. For all events, at all time-points, overall health care costs were signifi-
cantly higher in cases than controls. The mean incremental cost (2012 US$) 30 days 
after the event was: IS-$20,710; MI- $32,535; SE-$15,754; ICH-$45,242; and GI bleed-
$14,823. At all time-points ICH was the most costly while SE and GI bleed were least 
costly. ConClusions: This study is the first to describe AF-specific incremental 
costs of multiple types of ischemic and bleeding events, prior to NOAC availability. 
Our results provide tools to assess the value of NOACs.
PCV42
Cost ConsEquEnCE AnAlysis of APixAbAn VERsus WARfARin in PAtiEnts 
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objeCtives: The standard of care for patients with atrial fibrillation (AF) is war-
farin. However, warfarin use is limited by a narrow therapeutic range and docu-
mented risk of bleeding. This study aims to compare expected costs and clinical 
consequences of the usage of apixaban versus warfarin in the Mexican popula-
tion AF setting. Methods: A hypothetical patient cohort of 7,348 was evaluated, 
estimated from AF prevalence in 1,000,000 Mexicans. A decision tree model was 
developed considering annual costs and annual clinical consequences for both 
treatments. Effectiveness measures included the number of events for (1) stroke/
systemic embolism, (2) bleeding and (3) mortality. Event costs were estimated for 
each group. Under a conservative scenario, mortality events and INR monitoring 
were not considered. Rates for stroke, mortality and bleeding were extracted from 
the ARISTOTLE trial. Costs were estimated from a public health care perspective. 
Costs of treatment of events related to stroke and major bleeding corresponds to 
Diagnostic Related Groups published by IMSS. All costs are expressed in 2013 USD 
($1USD= $13MXN). Sensitivity analysis was performed. Results: Total number of 
events was lower for the apixaban cohort, the yearly stroke/systemic embolism 
events relative risk reduction was 21% versus the warfarin cohort (93 vs. 118 events, 
respectively), while the relative risk reduction of bleeding events was 31% (157 vs. 
227). Apixaban had an 11% relative risk reduction vs. warfarin in all cause mortal-
ity, with warfarin having 31 more mortality events for this cohort. The total cost of 
events for warfarin group was $600,849 for stroke/systemic embolism events and 
$742,011 for bleeding events while for apixaban group it was $476,924 and $511,483, 
respectively. Total costs of events were 26% higher for warfarin group ($1,342,860 vs. 
$988,407). ConClusions: The better clinical profile of apixaban when compared 
with warfarin has also important financial implications in terms of lower treatment 
costs for the events considered.
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objeCtives: The prevalence of venous thromboembolism (VTE) has been increas-
ing in China. However, the economic burden of the disease is not well understood. 
This study aims to estimate inpatient costs of VTE in China and identify key factors 
associated with costs. Methods: Hospitalizations with a diagnosis of VTE (includ-
ing deep vein thrombosis (DVT) or pulmonary embolism (PE)) were identified in 
a large hospital electronic medical record database that included 100% inpatient 
records from two tertiary hospitals between January 1st, 2010 and June 30th, 2013. 
Total costs per hospitalization as well as its components, pharmacy costs (all drug-
related costs) and non-pharmacy costs (all other costs), were estimated using hos-
pital billing data (in 2013 CNY) and converted to 2013 USD using an exchange rate 
of 6.12. Multivariate regressions were performed to assess factors associated with 
total hospitalization costs, including patient demographics, insurance status, VTE 
type, VTE diagnosis type, anticoagulant treatment, comorbidities, admission type, 
and surgical procedure. Results: A total of 1,047 VTE-related hospitalizations were 
included in the analysis. The mean age at hospitalization was 62.4 years and 54.1% 
of hospitalizations occurred to men. DVT accounted for 77.1% of the total hospitali-
zations. The average pharmacy, non-pharmacy, and total costs per hospitalization 
were CNY 9,820 (USD 1,604), CNY 19,294 (USD 3,153), and CNY 29,114 (USD 4,757), 
respectively. Diagnosis of PE (vs. DVT), anticoagulant treatments (vs. no anticoagu-
lant treatment), admission under critical condition, having surgical procedures, 
certain comorbidities, and VTE as secondary diagnosis were significantly associated 
with higher total costs per hospitalization (P < 0.05). ConClusions: In China, the 
inpatient costs of VTE are as high as 1.7 times of the average annual household 
income. Multiple factors, including VTE type, treatments, admission condition, etc., 
are associated with inpatient costs among VTE patients. Future studies are indicated 
to understand the cost variations.
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objeCtives: Heart failure (HF) ranks among the most costly diseases in the US, 
with hospitalizations being the driving force behind HF costs. This study sought 
to examine the most recent costs of hospitalizations among patients with sys-
tolic HF and commercial insurance in the US. Methods: This is a retrospective, 
observational study using a large, nationally representative commercial insurance 
claims database. Adult patients aged 18-64 years with ≥ 1 inpatient or ≥ 2 outpa-
tient diagnoses of systolic HF (ICD-9-CM 428.2x, 428.4x) in 1/1/2008-1/31/2013 and 
≥ 12-months of claims data prior to the first systolic HF diagnosis (index date) 
were included. Patients were followed until inpatient death or the end of the 
study period. Demographic and clinical characteristics and costs (health plan paid 
amount in 2013 dollars) of hospitalizations were summarized. Analyses focused 
on all-cause hospitalizations, hospitalizations with HF as a discharge diagnosis, 
and hospitalizations without HF but with other cardiovascular conditions as dis-
charge diagnosis. Results: A total of 26,848 patients met the study criteria (mean 
age 54 (SD 8.6); 63% male), with a mean follow up of 572 (SD 446) days. Comorbid 
conditions were common among systolic HF patients (hypertension: 34%; diabetes: 
26%; dyslipidemia: 21%; arrhythmias: 20%). During the study period, there was a 
total of 37,656 all-cause hospitalizations with a mean cost of $37,816 (SD $70,361), 
25,593 HF hospitalizations with a mean cost of $40,392 (SD $73,507), and 10,383 non-
HF CV hospitalizations with a mean cost of $34,823 (SD $66,773). ConClusions: 
Hospitalizations for heart failure pose a substantial economic burden to commercial 
payers in the US. Interventions targeted at preventing HF hospitalizations would 
alleviate the economic burden associated with HF.
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objeCtives: Approximately 23% of adults have varicose veins; 6% have advanced 
chronic venous disease characterized by hyperpigmentation, edema, and venous 
ulceration. Given limited real-world evidence, this study assessed varicose vein 
treatment patterns and corresponding outcomes, including costs, in the United 
States. Methods: A retrospective study was conducted using health care claims 
data from the Truven Health MarketScan database. Patients ≥ 18 years of age diag-
nosed with varicose veins between January 1, 2008 and June 30, 2012 were followed 
for 2 years post- diagnosis. Patients were classified into cohorts based on the pres-
ence and type of invasive treatment, and characterized by baseline symptomatic 
(ICD-9 codes: 454.0x, 454.1x, 454.2x, 454.8x) or asymptomatic (ICD-9 454.9x) disease, 
demographics and Thomson-Reuters Disease Stage. Retreatment rates, health care 
utilization and costs were compared across cohorts. Results: A total of 144,098 
patients met the study criteria. Mean age was 57 years, and 71% were female. 
Approximately 70% of patients received active surveillance/compression therapy; 
the remainder received invasive therapy (laser ablation, radiofrequency ablation, 
sclerotherapy, or surgery). Compared to the surveillance cohort, patients receiving 
invasive therapy were younger (53 years vs 58 years, p< 0.0001) and more likely to be 
female (76.5% vs 68.3%; p< 0.0001) and have symptomatic disease (81.2% vs 63.9%; 
p< 0.0001). Among those with invasive therapy, 25% received retreatment, with asso-
ciated 2-year treatment-specific costs around $6,800. Total 2-year costs for active 
surveillance (~$17,000) were lower compared to those with invasive therapies, espe-
cially compared to those with retreatment (~$19,000) (p< 0.0001). ConClusions: 
About 30% of patients with diagnosed varicose veins received invasive therapy; they 
were more likely to be younger, female and symptomatic. About 25% of patients 
receiving invasive therapy were re-treated within 6 months of diagnosis, with high-
